NJNicklas Järvelä Johansen

Nicklas Järvelä Johansen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicklas Järvelä Johansen has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Filip Krag Knop

    Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

    6 shared publications
  • Tina Vilsbøll

    Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

    4 shared publications
  • Camilla Schlüntz

    Center for Clinical Metabolic Research, Gentofte Hospital University of Copenhagen Hellerup Denmark

    3 shared publications
  • Asger Lund

    Center for Clinical Metabolic Research, Gentofte Hospital University of Copenhagen Hellerup Denmark

    2 shared publications
  • Asger Lund

    Centre for Clinical Metabolic Research, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

    2 shared publications
  • Henrik U. Andersen

    Steno Diabetes Center Copenhagen Gentofte Denmark

    2 shared publications

Latest Publications

  • The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes

    by Nicklas Järvelä Johansen, Filip Krag Knop

    In type 1 diabetes, average life expectancy is reduced by ˃10 years as compared with outside of diabetes. Residual cardiovascular risk defines high cardiovascular event rate despite modern, guideline-recommended standard of care of established risk factors like hypertension, dyslipidaemia, and glycaemic control, and it adds importantly to these lost years of life in type 1 diabetes due to atherosclerotic cardiovascular diseases like myocardial infarction and ischaemic stroke. With a growing understanding of inflammation as an important driver of atherosclerotic cardiovascular disease, residual inflammatory risk is a novel and common risk factor and a promising target for lowering residual cardiovascular risk in type 1 diabetes. Interestingly, the inexpensive anti-inflammatory agent colchicine reduced the risk of major adverse cardiovascular events by 25% in cardiovascular outcome trials in the secondary prevention of atherosclerotic cardiovascular disease. Here, we summarize the role of inflammation as a driver of atherosclerosis and review current evidence linking inflammation and atherosclerotic cardiovascular disease in type 1 diabetes. Also, we provide an overview of the evidence base for targeting residual inflammatory risk with colchicine for lowering residual cardiovascular risk in type 1 diabetes.


  • Effects of short‐acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes

    by Nicklas J. Johansen, Thomas F. Dejgaard, Asger Lund, Camilla Schlüntz, Bolette Hartmann, Jens J. Holst, Tina Vilsbøll, Henrik U. Andersen, Filip K. Knop

    Aim: To evaluate the efficacy of the short‐acting glucagon‐like peptide‐1 receptor agonist, exenatide, added to insulin therapy in type 1 diabetes on bone mineral density and bone turnover markers. Materials and Methods: In a randomized, double‐blinded, parallel‐group trial, 108 individuals with type 1 diabetes aged 18 years or older on basal‐bolus therapy with HbA1c 59‐88 mmol/mol (7.5%‐10.0%) and body mass index of more than 22.0 kg/m 2 were randomized (1:1) to preprandial subcutaneous injection of 10 μg exenatide (Byetta) before breakfast, lunch, and dinner over 26 weeks as add‐on treatment to insulin therapy. Results: Exenatide elicited a body weight reduction of 4.4 kg compared with placebo, but no between‐group differences in bone mineral density, as assessed by whole‐body, hip, lumbar, and forearm dual‐energy X‐ray absorptiometry following 26 weeks of treatment, were observed. Fasting plasma levels of C‐terminal telopeptides of type I collagen, a marker of bone resorption, and amino‐terminal propeptide of type I procollagen, a marker of bone formation, were unchanged by exenatide compared with placebo after 26 weeks. Conclusions: Despite an exenatide‐induced body weight reduction, no changes in bone metabolism were observed with exenatide added to insulin therapy in type 1 diabetes after 26 weeks.


  • Open Access

    Effect of short‐acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double‐blind placebo‐controlled trial

    by Nicklas J. Johansen, Thomas F. Dejgaard, Asger Lund, Camilla Schlüntz, Emil L. Larsen, Henrik E. Poulsen, Jens P. Goetze, Holger J. Møller, Tina Vilsbøll, Henrik U. Andersen, et al.

    Aims: To investigate the effect of adding the short‐acting glucagon‐like peptide 1 receptor agonist (GLP‐1RA) exenatide to insulin treatment on markers of cardiovascular risk in type 1 diabetes. Materials and methods: In a randomized, double‐blind, parallel‐group trial, 108 individuals with type 1 diabetes aged ≥18 years on multiple daily injection therapy with a body mass index >22.0 kg/m 2 and glycated haemoglobin concentration of 59 to 88 mmol/mol (7.5%−10.0%) were randomized (1:1) to preprandial subcutaneous injection of 10 μg exenatide (Byetta®) or placebo three times daily over 26 weeks as add‐on treatment to existing insulin therapy. Reported markers of cardiovascular risk were secondary endpoints and were analyzed in a baseline‐adjusted linear mixed model in the intention‐to‐treat population. The primary results of this study, the MAG1C (Meal‐time Administration of exenatide for Glycaemic control in type 1 diabetes Cases) trial, were previously reported. Results: Exenatide changed total fat mass by −2.6 kg (95% confidence interval [CI] −3.6; −1.6; P < 0.0001) and lean body mass by −1.1 kg (95% CI −1.9; −0.4; P = 0.01) compared with placebo, as assessed by dual‐energy X‐ray absorptiometry. Fat mass reductions were similar for central and peripheral fat mass. Exenatide did not change levels of interleukin‐2 or ‐6; tumour necrosis factor‐α; C‐reactive protein; N‐terminal prohormone of brain natriuretic peptide; or 8‐oxo‐7,8‐dihydroguanosine (RNA oxidation marker) and 8‐oxo‐7,8‐dihydro‐2′‐deoxyguanosine (DNA oxidation marker). Conclusions: Exenatide added to insulin therapy in type 1 diabetes for 26 weeks resulted in body weight loss primarily from fat mass reduction, but had no effect on biomarkers of cardiovascular disease risk.


  • Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial

    by Nicklas J Johansen, Thomas F Dejgaard, Asger Lund, Camilla Schlüntz, Christian S Frandsen, Julie L Forman, Nicolai J Wewer Albrechtsen, Jens J Holst, Ulrik Pedersen-Bjergaard, Sten Madsbad, et al.


  • The efficacy and safety of exenatide once weekly in patients with type 2 diabetes

    by Sebastian M. Heimbürger, Andreas Brønden, Nicklas J. Johansen, Thomas F. Dejgaard, Tina Vilsbøll, Filip K. Knop

    Exenatide once weekly (QW) is a glucagon-like peptide 1 receptor agonist (GLP-1RA) that was approved in 2012 in Europe and the U.S.A. for the treatment of type 2 diabetes (T2D). Areas covered: This review provides an overview of the safety and efficacy of exenatide QW for the treatment of T2D and evaluates the benefit-risk ratio compared to other available long-acting GLP-1RAs. In addition, the authors provide an outline of the novel formulations and delivery methods of exenatide. Expert opinion: Exenatide QW is an efficacious and safe treatment for T2D. However, head-to-head trials have demonstrated exenatide QW to be inferior to liraglutide and semaglutide with respect to effects on fasting plasma glucose, glycated hemoglobin A1c, and bodyweight. In addition, exenatide QW appears inferior to liraglutide and semaglutide in terms of cardiovascular risk reduction. Currently, the overall risk-benefit profiles for the range of GLP-1RAs point to liraglutide and semaglutide as first-choice for the management of T2D, which has been confirmed by a recently published consensus report on the treatment of T2D from the American Diabetes Association and the European Association for the Study of Diabetes. The pricing of exenatide QW will most likely be a key determinant for its place in the future management of T2D.


  • Open Access

    Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial

    by Nicklas Järvelä Johansen, Thomas Fremming Dejgaard, Asger Lund, Tina Vilsbøll, Henrik Ullits Andersen, Filip Krag Knop

    Introduction: Persons with type 1 diabetes require intensive insulin therapy to achieve glycaemic control, but side effects, including hypoglycaemia and weight gain, may reduce treatment compliance. We hypothesise that add-on treatment of the short-acting glucagon-like peptide-1 receptor agonist, exenatide, to insulin therapy in persons with type 1 diabetes will reduce insulin requirements, glycaemic excursions and body weight and improve glycaemic control without increasing the risk of hypoglycaemia. The present article describes a protocol developed to test this hypothesis. Methods and analysis: One-hundred adult persons with type 1 diabetes for more than 1 year, insufficient glycaemic control (glycated haemoglobin A1c (HbA1c) between 58 and 86 mmol/mol) and body mass index >22.0 kg/m 2 will be randomised to either exenatide 10 µg three times per day (at meal times) or placebo as add-on therapy to regular basal–bolus insulin treatment for 26 weeks. Primary endpoint is change in HbA1c between the two groups at end of treatment. Secondary endpoints include change in glycaemic excursions (assessed by continuous glucose monitoring); insulin dose; hypoglycaemic and adverse events; body weight, lean body and fat mass; dietary patterns; quality of life and treatment satisfaction; cardiovascular-disease risk profile; metabolomics; and arginine-tested plasma glucose, glucagon and C-peptide levels. Ethics and dissemination: The study is approved by the Danish Medicines Agency, the Regional Scientific Ethics Committee of the Capital Region of Denmark and the Data Protection Agency. The study will be carried out under the surveillance and guidance of the good clinical practice (GCP) unit at Copenhagen University Hospital Bispebjerg in accordance with the ICH-GCP guidelines and the Helsinki Declaration. Positive, negative as well as inconclusive results will be sought disseminated at scientific meetings and in international peer-reviewed scientific journals. Trial registration number: NCT03017352 .


  • A Systematic Review on Insulin Overdose Cases: Clinical Course, Complications and Treatment Options

    by Nicklas Järvelä Johansen, Mikkel Bring Christensen

    A large overdose of insulin is a serious health matter. Information concerning administration and duration of intravenous (IV) glucose, other treatment options or complications besides hypoglycaemia following large insulin overdoses is not readily apparent from the literature. A systematic search, compilation and review of case reports on insulin overdoses, published 1986–2017, was performed in PubMed, EMBASE, Cochrane and PROSPERO databases. Of 1523 published articles, 45 cases of insulin overdoses were included with a total median insulin dose of 900 international units (IU) (range 26–4800 IU). Hospitalization occurred in 44 cases with a median hospitalization duration of 94 hr (range 12–721 hr), and one‐third (n = 15) admitted to the intensive care unit. First‐line treatment was IV glucose treatment in 95% of cases. Treatment options besides IV glucose that were reported beneficial included glucagon IV or intramuscular (IM), octreotide IV or IM, surgical excision, hydrocortisone IV and oral intake of complex carbohydrates. Prevalent complications were intermittent cerebral impairment (73%), hypokalaemia (49%), other electrolyte disturbances (42%), and hepatic disturbances (7%) and cardiac toxicity (e.g. cardiac arrhythmia) (9%). Long‐term consequences were one case of lasting hypoglycaemic encephalopathy and one death. In conclusion, following large insulin overdoses, in‐hospital admission and treatment with IV glucose may be needed for up to a week. Monitoring of electrolytes and hepatic and cardiac functions seems important. Several experimental treatment options may be considered in addition to glucose administration. With appropriate pre‐ and in‐hospital treatment, cases with severe hypoglycaemia and neurologic complications may have a favourable outcome.